Dube Michael P
VP, Chief Accounting Officer
Dube Michael P has filed 4 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: Jul 6, 2026.
On the most recent filing, Dube Michael P is listed as VP, Chief Accounting Officer at Intellia Therapeutics, Inc. Inside the rolling window, Dube Michael P reported no open-market purchases and 3 open-market sales totaling $104K in NTLA. The largest disclosed transaction in the window is a sale of 2,641 NTLA shares on Jul 1, 2026, worth $44K.
Companies traded
Other insiders at NTLA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$104K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Dube Michael P made?
Dube Michael P has filed 4 SEC Form 4 filings (4 transaction rows) across 1 company since 2025.
Which companies does Dube Michael P trade?
Dube Michael P has filed SEC Form 4 disclosures for 1 company, including NTLA.
When was Dube Michael P's most recent SEC Form 4 filing?
Dube Michael P's most recent SEC Form 4 filing on Tracefour is dated Jul 6, 2026.
What is Dube Michael P's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Dube Michael P is listed as VP, Chief Accounting Officer.
What is Dube Michael P's total buy and sell value in the current window?
Inside the rolling retention window, Dube Michael P bought $0 and sold $104K based on SEC Form 4 filings.
What was Dube Michael P's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 2,641 NTLA shares on 2026-07-01, worth $44K, per SEC Form 4 filings.